Johnson & Johnson (JNJ)
Pre-market:
| Previous close | 147.91 |
| Open | 148.51 |
| Bid | 149.44 x 900 |
| Ask | 149.92 x 900 |
| Day's range | 147.30 - 150.27 |
| 52-week range | 143.13 - 175.97 |
| Volume | |
| Avg. volume | 7,515,895 |
| Market cap | 359.346B |
| Beta (5Y monthly) | 0.53 |
| PE ratio (TTM) | 20.07 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 4.96 (3.33%) |
| Ex-dividend date | 20 May 2024 |
| 1y target est | N/A |
- Insider Monkey
10 Best Performing Biotech ETFs in 2024
In this article, we discuss the 10 best performing biotech ETFs in 2024. If you want to skip our detailed introduction to the biotech industry and just want to take a look at some more ETFs, go directly to the 5 Best Performing Biotech ETFs in 2024. Biotechnology is a challenging field, not ideal for […]
- Zacks
Johnson & Johnson (JNJ) Is a Trending Stock: Facts to Know Before Betting on It
Johnson & Johnson (JNJ) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
- Reuters
RPT-Contaminated cough syrup in Africa no longer available - WHO
A contaminated batch of Benylin Paediatric Syrup is no longer available in the African countries where it was sold, the World Health Organization said on Monday. Earlier this month, Nigeria recalled a batch of the children's cough and allergy medicine after tests found that it contained unacceptable levels of the toxin, diethylene glycol. Five other African countries have also pulled the product from shelves - Kenya, Rwanda, Tanzania, Zimbabwe and South Africa, where the drug was made.
